GGrantIndex
Sort

261,768 grants matching gene therapy

Polypeptide Microbicides Targeting CCR5

$1,368,411
University Of Md Biotechnology Institute · P01 · FY2003 · AI

Integrated Systems Biology Approach to Diabetic Microvascular Complications

$1,368,284
Eva L Feldman · University Of Michigan At Ann Arbor · R24 · FY2019 · DK

HIV persistence in vivo

$1,368,258
Eli Boritz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters

$1,368,236
Gordon M Ringold · Quadriga Biosciences, Inc. · R44 · FY2021 · CA

Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis

$1,368,144
Shabaana A. Khader · University Of Chicago · R01 · FY2024 · AI

Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis

$1,368,144
Shabaana A. Khader · University Of Chicago · R01 · FY2025 · AI

A first in human clinical study of TT101, a synthetic immunomodulatory material to build new functional tissue over exposed bone as a one time treatment for diabetic limb preservation patients

$1,368,090
Stephanie Deshayes · Tempo Therapeutics, Inc. · R44 · FY2021 · DK

Molecular Therapeutics for Epithelial Disorders

$1,367,983
Stanford University · P01 · FY2002 · AR

Improving the Outcome of Patients with Chronic Myeloid Leukemia Through Medi

$1,367,891
Jorge E Cortes · University Of Tx Md Anderson Can Ctr · P01 · FY2012 · CA

Lambda Genetic Networks and Lambda Red-Mediated Recombination

$1,367,570
Donald Court · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Cell Survival and Cancer

$1,367,486
Thomas Jefferson University · P01 · FY2005 · CA

ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR HIV/AIDS

$1,367,405
Miriam Hospital · U01 · FY2004 · AI

Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial

$1,367,380
John R Guy · University Of Miami School Of Medicine · U10 · FY2016 · EY

Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes

$1,367,242
Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis

$1,367,116
Robert A Lafyatis · University Of Pittsburgh At Pittsburgh · P50 · FY2019 · AR

The Pathogenesis, Diagnosis, and Treatment of Systemic Mast Cell Disorders

$1,366,986
Hirsh D Komarow · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Immune Function and the Progression to Type 1 Diabetes

$1,366,867
Mark A Atkinson · University Of Florida · P01 · FY2018 · AI

Novel Therapeutics for Class B Protozoa

$1,366,784
Sharon L Reed · University Of California, San Diego · U01 · FY2011 · AI

NF-kB Inhibition Therapy for Duchenne Muscular Dystrophy

$1,366,658
Denis C Guttridge · Ohio State University · U01 · FY2011 · NS

NF-kappaBeta Therapy for Duchenne Muscular Dystrophy

$1,366,658
Denis C Guttridge · Ohio State University · U01 · FY2011 · NS

Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease

$1,366,586
David Radin · Biostrategies, Lc · R44 · FY2017 · NS

NF-kB Inhibition Therapy for Duchenne Muscular Dystrophy

$1,366,577
Denis C Guttridge · Ohio State University · U01 · FY2010 · NS

Molecular Analysis Of Retroviral Genes And Their Products

$1,366,460
Klaus Strebel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

The LUCINDA Trial

$1,366,388
Tracy A. Butler · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · AG

H. pylori-induced Inflammation and Gastric Cancer

$1,366,185
Richard M Peek · Vanderbilt University Medical Center · P01 · FY2021 · CA